Small Molecule and Novel Treatments for Chronic Hepatitis C Virus Infection
- 1 October 2007
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 102 (10) , 2332-2338
- https://doi.org/10.1111/j.1572-0241.2007.01397.x
Abstract
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)Keywords
This publication has 25 references indexed in Scilit:
- 78 The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1 PEG-IFNα-2b non-responders: Antiviral activity and HCV variant analysisJournal of Hepatology, 2006
- 601 Anti-viral activity of VX-950 resolves expression of an HCV-associated gene signatureJournal of Hepatology, 2006
- 624 Absence of effect of pegylated interferon alpha-2b on the pharmacokinetics of valopicitabine (NM283) in patients with chronic hepatitis CJournal of Hepatology, 2006
- 39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 resultsJournal of Hepatology, 2006
- 12 Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCVJournal of Hepatology, 2006
- 751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 resultsJournal of Hepatology, 2006
- 737 Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2aJournal of Hepatology, 2006
- 736 Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb trialJournal of Hepatology, 2006
- 623 Safety and pharmacokinetics of NM107 following intravenous infusion of escalating doses in healthy volunteers: Determination of absolute oral bioavailability of valopicitabine (NM283)Journal of Hepatology, 2006
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999